Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
35.44
+1.23 (3.60%)
At close: Oct 9, 2026, 4:00 PM EDT
35.57
+0.13 (0.37%)
After-hours: Oct 9, 2026, 7:55 PM EDT
Roivant Sciences Employees
Roivant Sciences had 721 employees as of March 31, 2026. The number of employees decreased by 29 or -3.87% compared to the previous year. That makes Roivant Sciences the 17,275th largest employer in the world and 2,400th in the United States.
Employees
721
Change (1Y)
-29
Growth (1Y)
-3.87%
Revenue / Employee
$10,447
Profits / Employee
-$369,283
Market Cap
25.60B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 721 | -29 | -3.87% |
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
ROIV News
- 18 days ago - Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback - TheFly
- 18 days ago - Roivant Sciences price target raised to $41 from $37.50 at BofA - TheFly
- 18 days ago - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - GlobeNewsWire
- 18 days ago - Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - GlobeNewsWire
- 19 days ago - Roivant Sciences Transcript: Bank of America Global Healthcare Conference - Transcripts
- 25 days ago - Roivant Sciences initiated with a Buy at Stifel - TheFly
- 4 weeks ago - Roivant Sciences Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 weeks ago - Roivant Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts